Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Rev Sci Instrum ; 83(2): 02A346, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22380193

ABSTRACT

We have developed an electron cyclotron resonance ion source apparatus, which is designed for the production of endohedral fullerene. In this study, we irradiated the Fe(+) beam to the C(60) thin film. We changed the experimental condition of the dose and the ion energy. We could observe the Fe + C(60) peak by analysis of the time-of-flight mass spectrometry. The highest intensity of the Fe + C(60) peak was observed at the ion energy of 200 eV. The Fe + C(60) peak intensity tended to become high in the case of long irradiation time and large dose.


Subject(s)
Electrons , Fullerenes/chemistry , Iron/chemistry , Radiation Dosage
2.
Rev Sci Instrum ; 81(2): 02A306, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20192327

ABSTRACT

We developed an electron cyclotron resonance ion source (ECRIS) for new materials production on nanoscale. Our main target is the endohedral fullerenes, which have potential in medical care, biotechnology, and nanotechnology. In particular, iron-encapsulated fullerene can be applied as a contrast material for magnetic resonance imaging or microwave heat therapy. Thus, our new ECRIS is named the Bio-Nano ECRIS. In this article, the recent progress of the development of the Bio-Nano ECRIS is reported: (i) iron ion beam production using induction heating oven and (ii) optimization of singly charged C(60) ion beam production.


Subject(s)
Cyclotrons , Electrons , Nanotechnology/methods , Fullerenes/chemistry , Hot Temperature , Nanotechnology/instrumentation
3.
Clin Exp Allergy ; 38(3): 405-12, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18070160

ABSTRACT

BACKGROUND: Allergic rhinitis (AR) is a typical type I allergic disease that occurs through the induction of allergen-specific effector T cells. Once established, new effector T cells derive mostly from memory T cells that are capable of surviving for extended periods, although the mechanisms by which these memory functions are maintained have not yet been clarified. In particular, the exact life-span of memory T cells is still not well understood. OBJECTIVE: Pollinosis patients seemed to be suitable subjects to investigate because such patients are exposed to antigens strongly for only a limited period once a year. We compared the seasonal changes in memory T-helper type 2 (Th2) between pollinosis and perennial allergic subjects. METHODS: The clone sizes of the Japanese cedar pollen-specific memory Th cells were measured by an ELISPOT assay using specific peptides from the patients with cedar pollinosis, and the seasonal changes were noted. This study was performed for 2 years. The cedar-specific IgE levels in the peripheral blood were also studied. Mite allergy patients were also enrolled in the study. RESULTS: The Japanese cedar-specific IL-4-producing Th2 cells were detected in all patients examined, although the number of cells was low. These Th memory cells increased during the pollen season and decreased during the off-season. However, more than 60% of the cedar-specific memory Th2 cells survived up to 8 months after the pollen season. The cedar-specific IgE levels exhibited changes similar to the cedar-specific Th cells. On the other hand, there was no drifting of Th memory clone size with the mite allergics, and the IgE levels also did not change. CONCLUSIONS: While pollen-specific Th cells decreased after pollen exposure, their memory functions continued. Memory clone size maintenance therefore requires repetitive antigen irritation.


Subject(s)
Cryptomeria/immunology , Rhinitis, Allergic, Seasonal/immunology , Rhinitis, Allergic, Seasonal/pathology , Seasons , Th2 Cells/immunology , Th2 Cells/pathology , Adult , Animals , CD4 Lymphocyte Count , Clone Cells/pathology , Epitopes , Female , Humans , Immunoglobulin E/blood , Immunoglobulin E/immunology , Immunologic Memory , Interleukin-4/biosynthesis , Male , Middle Aged , Pollen/immunology , Pyroglyphidae/immunology , Rhinitis, Allergic, Perennial/immunology , Rhinitis, Allergic, Perennial/pathology , Th2 Cells/metabolism
4.
Clin Nephrol ; 68(2): 93-8, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17722708

ABSTRACT

AIMS: Histamine H2 receptor antagonists (HRA) or proton pump inhibitors (PPI) are frequently administered to patients on hemodialysis, because their intestinal mucosa is fragile. Although three studies have indicated that concomitant HRA administration causes a decrease in the binding of phosphate by calcium carbonate, the HRA doses tested in these studies were 2-4 times higher than the recommended dose for hemodialysis patients. In addition, it remains unclear whether PPI therapy affects serum phosphate levels in hemodialysis patients taking calcium carbonate. Accordingly, the aim of this study was to evaluate the influence of lansoprazole and the recommended dose of famotidine on serum phosphate and calcium levels in hemodialysis patients. METHODS: The study included 115 hemodialysis patients who were taking calcium carbonate and who were also treated with either famotidine (10 mg/day) or lansoprazole (30 mg/day). Changes of the mean serum phosphate and calcium levels over 2 months before and after the start of famotidine or lansoprazole therapy were compared. The same parameters were also compared when famotidine was switched to lansoprazole. RESULTS: The mean serum phosphate level increased significantly after administration of either famotidine or lansoprazole (by 6.6 +/- 21.9% or 13.0 +/- 26.3%, p = 0.032 and p = 0.029, respectively). The mean serum calcium level was unchanged after administration of famotidine, but showed a significant decrease after administration of lansoprazole (by 3.44 +/- 7.73%, p = 0.013). Therefore, the calcium x phosphorus product was significantly increased by administration of famotidine, but not by administration of lansoprazole (6.68 +/- 23.37% and 8.73 +/- 27.41%, p = 0.046 and p = 0.251, respectively). When famotidine was switched to lansoprazole, the serum phosophate level did not change, but serum calcium decreased significantly by 3.8 +/- 13.0% (p = 0.0006). CONCLUSION: Not only administration of 20 mg/ day of famotidine as previously reported, but also 10 mg/day of this drug (the recommended dose for hemodialysis patients) caused a significant increase of serum phosphate in patients taking calcium carbonate. PPIs have been reported to show no effect on the serum phosphate level, but 30 mg/day of lansoprazole also caused a significant increase of serum phosphate in patients taking calcium carbonate.


Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/pharmacology , Calcium Carbonate/therapeutic use , Famotidine/pharmacology , Histamine H2 Antagonists/pharmacology , Phosphorus/blood , Proton Pump Inhibitors , Renal Dialysis , Female , Humans , Lansoprazole , Male , Middle Aged
5.
Drugs Exp Clin Res ; 31(5-6): 207-14, 2005.
Article in English | MEDLINE | ID: mdl-16425977

ABSTRACT

Juzen-Taiho-To (JTT) is a Japanese herbal medicine that has been administered mainly to patients weakened by long illness. Currently, it has also been used for cancer patients and showed antitumor effects that have been reported as phagocytosis enhancement, cytokine induction and antibody production. In this study, we examined the effect of oral administration of JTT in mice on the immunological restoration of the liver, especially focused on natural killer (NK) T-cell induction. Mice were grouped to receive JTT or placebo orally for a period of 1, 3 and 7 days. After sacrifice, the liver tissue was fixed, embedded and stained with hematoxylineosin and some antibodies by common staining methods. Transmission electron microscope (TEM) observation was also carried out. Although the JTT-treated mice had the same appearance as the non-JTT-treated mice, their livers were infiltrated by massive mononuclear cells, some of which were aggregated in clusters. Immunohistochemical staining revealed that there was abundant cytokine expression of interleukin (IL)-12 and massive infiltration of mononuclear cells with large granules in the liver of JTT-treated mice. Oral administration of JTT may induce the expression of IL-12 and be followed by immunological restoration such as NK T-cell induction in liver


Subject(s)
Antineoplastic Agents/pharmacology , Drugs, Chinese Herbal/pharmacology , Leukocytes, Mononuclear/pathology , Liver/drug effects , Animals , Cytokines/biosynthesis , Female , Immunohistochemistry , Interleukin-12/biosynthesis , Killer Cells, Natural/immunology , Leukocytes, Mononuclear/metabolism , Liver/immunology , Liver/pathology , Mice , Mice, Inbred C57BL , Microscopy, Electron, Transmission
6.
Urology ; 55(4): 495-500, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10736490

ABSTRACT

OBJECTIVES: To evaluate the anticancer effects of a lipophilic macromolecular anticancer agent, poly(styrene-co-maleic acid)-conjugated neocarzinostatin (SMANCS), dissolved in a lipid contrast medium (Lipiodol) given via the renal artery to patients with renal cell carcinoma. METHODS: Among 467 patients with renal cell carcinoma treated between April 1984 and March 1993, 191 were treated with SMANCS dissolved in a lipid contrast medium (a 3:2 mixture of Lipiodol F and Lipiodol Ultrafluid; Lpd). Selective arterial infusion of SMANCS/Lpd was performed at a dose of 1.0 or 1. 5 mg/mL. The infusion was repeated at intervals of about 2 weeks or longer, but the doses and the total number of infusions varied among patients, according to results of computed tomography analysis. RESULTS: Statistical analysis was performed for 415 patients who met the criteria of this study. Twenty-six surgical patients with metastases who underwent infusion therapy of SMANCS/Lpd for primary lesions showed 3 and 5-year survival rates of 23.0% and 12.8%, respectively; the rates were 19.3% and 9.7% in 31 patients who did not receive SMANCS infusion therapy. In 125 surgical patients without metastases who underwent SMANCS/Lpd infusion, the 5 and 10-year survival rates were 83.0% and 75.2%, respectively, whereas rates of 84.6% and 78.9% were observed in 199 surgical patients whose median tumor size was significantly smaller, however, than the SMANCS/Lpd infusion group. The maximal tumor diameter at the beginning of treatment was significantly larger (mean diameter 70.8 mm) in the SMANCS/Lpd infusion group than in the noninfusion group (59.1 mm). The survival rate was statistically better for patients with tumors of 100 mm diameter or larger in the SMANCS/Lpd infusion group (P <0.05): 5 and 10-year survival rates were 70.4% and 61.6%, respectively, for the infusion group and 64.6% and 50.9% for the group receiving no drug. In patients with larger tumor (greater than 110 mm), the survival rate at 13 years was 75% in the SMANCS/Lpd infusion group and 0% in the surgery group. CONCLUSIONS: Arterial infusion therapy with SMANCS/Lpd appears to be effective for large renal cell carcinoma without metastases in conjunction with surgery.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Renal Cell/drug therapy , Infusions, Intra-Arterial , Iodized Oil/administration & dosage , Kidney Neoplasms/drug therapy , Maleic Anhydrides/administration & dosage , Polystyrenes/administration & dosage , Zinostatin/analogs & derivatives , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Humans , Iodized Oil/adverse effects , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Kidney Neoplasms/surgery , Male , Maleic Anhydrides/adverse effects , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Polystyrenes/adverse effects , Survival Rate , Tomography, X-Ray Computed , Treatment Outcome , Zinostatin/administration & dosage , Zinostatin/adverse effects
7.
J Cardiovasc Pharmacol ; 35(2): 203-11, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10672851

ABSTRACT

Endothelin-1 (ET-1) induces severe pathologic conditions such as coronary spasm followed by vasospastic angina pectoris and acute myocardial infarction. The related pathophysiologic mechanisms have remained obscure. Endothelin-1 receptor (ET(A) and ET(B)) is reported to couple with several types of G protein-involved pathways that participate in phospholipase C activation and atrial myofibrils organization into sarcomeric units. Here we demonstrate that ET-1 induces histologic and pathologic dysfunction in the rabbit myocardium and that such pathologic events are prevented by the Rho-kinase inhibitor fasudil. Although the bolus injection of ET-1 (1.4 nmol/kg) via the auricular vein of the rabbit induced only transient T-wave elevation, irreversible, severe histologic changes were observed in papillary muscles of the ventricle, and multifocal myocardial necrosis with infiltration of neutrophils and macrophages in the left ventricle occurred. Oral administration of fasudil (10 mg/kg) significantly reduced the occurrence of myocardial injury determinants, whereas conventional Ca2+ channel blockers (nifedipine, diltiazem) and a K+ channel opener (nicorandil; 10 mg/kg, p.o. each) showed a lesser or no effect on such determinants. These results suggest that ET-1 induces severe myocardial dysfunction based not only on the occurrence of vasospastic ischemia but also on its direct effects on the myocardium.


Subject(s)
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , Endothelin-1/antagonists & inhibitors , Enzyme Inhibitors/therapeutic use , Myocardial Ischemia/prevention & control , Papillary Muscles/drug effects , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Animals , Cell Movement/drug effects , Diltiazem/pharmacology , Electrocardiography/drug effects , Heart Ventricles/drug effects , Heart Ventricles/pathology , Macrophages/physiology , Male , Microscopy , Myocardial Ischemia/pathology , Necrosis , Neutrophils/physiology , Nicorandil/pharmacology , Nifedipine/pharmacology , Papillary Muscles/ultrastructure , Rabbits , Random Allocation , Vasodilator Agents/pharmacology
8.
Dis Colon Rectum ; 42(12): 1560-8, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10613474

ABSTRACT

PURPOSE: Functional outcome after low anterior resection for rectal cancer is improved by the construction of a colonic J-pouch. One disadvantage of this type of reconstruction is evacuation difficulty, which has been associated with large pouches. The purpose of this study was to elucidate the causes of evacuation difficulty in large pouches using pouchography. METHODS: The angle between the longitudinal axis of the pouch and the horizontal line (pouch-horizontal angle) on lateral pouchography was determined in 26 patients with 10-cm J-pouch reconstructions (10-J group) and 27 patients with 5-cm J-pouch reconstructions (5-J group). Measurement were made at three months, one year, and two years after surgery. Clinical function was evaluated using a questionnaire one year postoperatively. RESULTS: The pouch-horizontal angle in the 10-J group was significantly smaller than that in the 5-J group at all three time points. In both groups the pouch-horizontal angle at one year was significantly smaller than that at three months. There were no significant differences between the pouch-horizontal angles at one and two years. An evacuation difficulty was significantly more common in the 10-J group than the 5-J group. CONCLUSIONS: The evacuation difficulty observed in patients with large colonic J-pouch reconstructions may be attributed to the development of a horizontal inclination within one year of surgery.


Subject(s)
Colon/pathology , Defecation/physiology , Proctocolectomy, Restorative/methods , Adult , Aged , Anastomosis, Surgical/adverse effects , Anastomosis, Surgical/methods , Barium Sulfate , Chi-Square Distribution , Colon/diagnostic imaging , Colon/surgery , Contrast Media , Diatrizoate Meglumine , Enema , Female , Follow-Up Studies , Humans , Male , Middle Aged , Proctocolectomy, Restorative/adverse effects , Radiography , Rectal Neoplasms/surgery , Surveys and Questionnaires , Treatment Outcome
10.
J Neurochem ; 72(5): 1781-90, 1999 May.
Article in English | MEDLINE | ID: mdl-10217254

ABSTRACT

Recently, we showed that transfection of GD3 synthase cDNA into Neuro2a cells, a mouse neuroblastoma cell line, causes cell differentiation with neurite sprouting. In a search for the genes involved in this ganglioside-induced Neuro2a differentiation, we used a tetracycline-regulated GD3 synthase cDNA expression system combined with differential display PCRs to identify mRNAs that were differentially expressed at four representative time points during the process. We report here the identification of 10 mRNAs that are expressed highly at the Neuro2a differentiated stage. These cDNAs were named GDAP1-GDAP10 for (ganglioside-induced differentiation-associated protein) cDNAs. It is interesting that in retinoic acid-induced neural differentiated mouse embryonic carcinoma P19 cells, GDAP mRNA expression levels were also up-regulated (except that of GDAP3), ranging from three to >10 times compared with nondifferentiated P19 cells. All the GDAP genes (except that of GDAP3) were developmentally regulated. The GDAP1, 2, 6, 8, and 10 mRNAs were expressed highly in the adult mouse brain, whereas all the other GDAP mRNAs were expressed in most tissues. Our results suggested that these GDAP genes might be involved in the signal transduction pathway that is triggered through the expression of a single sialyltransferase gene to induce neurite-like differentiation of Neuro2a cells.


Subject(s)
DNA, Complementary/isolation & purification , Gene Expression Regulation/physiology , Nerve Tissue Proteins/genetics , Sialyltransferases/genetics , Aging/metabolism , Amino Acid Sequence/genetics , Animals , Brain/growth & development , Brain/metabolism , Cell Differentiation/physiology , Mice , Molecular Sequence Data , Tretinoin/pharmacology , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Tumor Cells, Cultured/pathology
11.
Connect Tissue Res ; 39(1-3): 111-22; discussion 141-9, 1998.
Article in English | MEDLINE | ID: mdl-11062993

ABSTRACT

Enamel proteins are cleaved by proteinases soon after their secretion by ameloblasts. Intact proteins concentrate in the outer enamel at or near the growing tips of the enamel crystallites while cleavage products accumulate in the deeper enamel. In the transition and early maturation stages there is a dramatic increase in proteolytic activity. This activity, coupled with the diminished secretory and increased reabsorptive functions of ameloblasts, leads to a precipitous fall in the amount of enamel protein in the matrix. Recently we have cloned and characterized an mRNA encoding a tooth-specific serine proteinase designated enamel matrix serine proteinase 1 (EMSP1) [Simmer et al., JDR (1998) 77: 377]. EMSP1 can be detected in the inner enamel during the secretory stage and its activity increases sharply during the transition stage. Stage-specific Northern blot analysis demonstrates this increase is accompanied by a parallel increase in the amount EMSP1 mRNA. A 3-dimensional computer model of EMSP1, based upon the crystal structure of bovine trypsin, has been generated and analyzed. All six disulfide bridges as well as the active site are conserved. Changes in the peptide binding region and the specificity pocket suggest that interaction of the proteinase with protein substrates is altered, potentially causing a shift in substrate specificity. The calcium binding region of trypsin is thoroughly modified suggesting that the calcium independence of EMSP1 activity is due to an inability to bind calcium. The three potential N-linked glycosylation sites, N104, N139 and N184, are in surface accessible positions away from the active site.


Subject(s)
Gene Expression Regulation, Developmental , Kallikreins , Models, Molecular , Serine Endopeptidases/chemistry , Serine Endopeptidases/genetics , Amino Acid Sequence , Animals , Base Sequence , Blotting, Northern/methods , Cattle , DNA, Complementary , Enamel Organ/growth & development , Molecular Sequence Data , Protein Conformation , RNA, Messenger/metabolism , Sequence Homology, Amino Acid , Serine Endopeptidases/metabolism , Swine , Trypsin/chemistry
12.
Biol Pharm Bull ; 20(1): 104-6, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9013820

ABSTRACT

The enhanced effect of urethane anesthesia on the serum creatine kinase (CPK) level following administration of hypolipidemic agents was examined to develop a convenient experimental screening method for drug-induced myopathy. After oral administration of a hypolipidemic agent to rats, 25% urethane solution was infused intravenously at a very low rate using a microinfusion pump. Blood samples were collected 7 h after drug administration and the risk of myopathy was evaluated based on the CPK level. When bezafibrate (BF), simvastatin (SV), or pravastatin (PV) (50-500 mg/kg) was orally administered under urethane infusion, enhanced elevation of the serum CPK level was observed dose dependently for BF and SV, but not for PV. The elevation of serum CPK was much higher with BF than with SV or PV. In addition, when SV or PV (50-500 mg/kg) was coadministered with 50 mg/kg of BF, there was a striking increase in the serum CPK level as compared with the drug alone. Without urethane infusion, no significant elevation in serum CPK level was observed even at a high dose of these hypolipidemic agents. These phenomena suggest that the urethane anesthesia enhanced the elevation of the serum CPK level following administration of hypolipidemic agents. We propose that this method is a simple and speedy screening test for drug-induced myopathy.


Subject(s)
Hypolipidemic Agents/adverse effects , Muscular Diseases/chemically induced , Anesthesia , Animals , Bezafibrate/adverse effects , Calcium/metabolism , Creatine Kinase/blood , Lovastatin/adverse effects , Lovastatin/analogs & derivatives , Male , Pravastatin/adverse effects , Rats , Rats, Wistar , Simvastatin , Urethane
13.
Am J Physiol ; 270(1 Pt 2): F1-8, 1996 Jan.
Article in English | MEDLINE | ID: mdl-8769817

ABSTRACT

Postresuscitation organ failure may be associated with detrimental changes in body fluid compartments. We measured how shock and resuscitation acutely alters the interstitial, cellular, and plasma compartments in different organs. Nephrectomized, anesthetized rats were bled to 50 mmHg mean arterial pressure for 1 h, followed by 60 min of resuscitation to restore blood pressure using 0.9% normal saline (NS,n = 10), 7.5% hypertonic saline (HS,n = 8), 10% hyperoncotic albumin (HA, n = 8), or 7.5% hypertonic saline and 10% hyperoncotic albumin (HSA, n = 7). A 2-h 51Cr-EDTA distribution space estimated extracellular fluid volume (ECFV), and a 5-min 125I-labeled albumin distribution space measured plasma volume (PV). Total tissue water (TW) was measured from wet and dry weights; interstitial fluid volume (ISFV) and cell water were calculated. NS resuscitation required 7 times more fluid (50.9 +/- 7.7 vs. 8.6 +/- 0.7 for HA, 5.9 +/- 0.4 for HS, and 3.9 +/- 0.5 ml/kg for HSA), but there were no differences between solutions in whole animal PV, ECFV, or ISFV. Fluid shifts within tissues depended on resuscitation solution and type of tissue. TW was significantly reduced by hypertonic saline groups in heart, muscle, and liver (P < 0.05). ISFV was significantly reduced by HA groups in the skin. In all tissues, mean cell water in groups receiving HS was smaller; this was significant for heart, lung, muscle, and skin. In conclusion, 1) HS solutions mobilize fluid from cells while expanding both PV and ISFV, and 2) TW and cellular water increase with both isotonic crystalloids and hyperoncotic colloids in many tissues.


Subject(s)
Albumins/therapeutic use , Body Fluid Compartments , Fluid Therapy , Plasma Substitutes/therapeutic use , Resuscitation , Shock, Hemorrhagic/physiopathology , Shock, Hemorrhagic/therapy , Animals , Crystalloid Solutions , Drug Combinations , Isotonic Solutions/therapeutic use , Male , Osmotic Pressure , Rats , Rats, Wistar , Rehydration Solutions/therapeutic use , Sodium Chloride/therapeutic use
14.
Int J Urol ; 3(1 Suppl): S55-9, 1996 Jan.
Article in English | MEDLINE | ID: mdl-24304026

ABSTRACT

For the past 50 years, transurethral resection of the prostate (TURP) has been the most common treatment for benign prostatic hyperplasia (BPH). The authors have conducted visual laser ablation of the prostate (VLAP) for BPH as a minimum invasive surgery. The results were compared with those of VLAP, VLAP+transurethral incision of the prostate (TUIP), and TURP as other treatments for BPH. In the VLAP group, 50 of 52 (96.2%), 36 of 40 (90.0%) and 31 of 36 (86.1%) were categorized as having more than a Fair Response (FR) at 3, 6 and 12 months, postoperatively. In the VLAP+TUIP group, 24 of 29 (82.8%), 19 of 22 (86.4%) and 9 of 11 (81.8%) were classed as having more than a FR at 3, 6 and 1 2 months, postoperatively. Forty-one of 42 (97.6%), 1 7 of 1 7 (100.0%) and 6 of 6 (100.0%) patients reaction to TURP was more than FR in overall response at 3, 6 and 12 months, postoperatively. The need for a blood transfusion, perforation of the prostate capsule and transit incontinence persisting for more than 1 month occurred in 1 of 45 (2.2%), 1 (2.2%) and 4 (8.9%) patients in the TURP group. Bladder neck contracture was seen in 4 of 52 (7.7%) in the VLAP group. Average postoperative catheter duration was shorter in the VLAP+TUIP (5.7 ± 8.4 days) than in the VLAP group (10.3 ± 10.4 days). Although TURP remains the standard treatment for BPH, VLAP results in less morbidity compared to TURP. VLAP with TUIP appears to lessen the risk of postoperative urinary retention and provide better results in longer follow-up studies.


Subject(s)
Laser Therapy/methods , Minimally Invasive Surgical Procedures/methods , Prostate/surgery , Prostatic Hyperplasia/surgery , Transurethral Resection of Prostate/methods , Aged , Aged, 80 and over , Follow-Up Studies , Humans , Laser Therapy/adverse effects , Laser Therapy/instrumentation , Male , Middle Aged , Minimally Invasive Surgical Procedures/instrumentation , Morbidity , Prostatic Hyperplasia/mortality , Transurethral Resection of Prostate/adverse effects , Transurethral Resection of Prostate/instrumentation , Treatment Outcome , Urinary Bladder Neck Obstruction/etiology , Urinary Bladder Neck Obstruction/mortality , Urinary Bladder Neck Obstruction/surgery
15.
Biochem Biophys Res Commun ; 216(1): 265-72, 1995 Nov 02.
Article in English | MEDLINE | ID: mdl-7488099

ABSTRACT

Using a mouse cDNA probe we have identified a human uridine phosphorylase cDNA clone from the cDNA library of a human colorectal tumor cell line, HCT116. The recombinant human uridine phosphorylase expressed in COS-7 cells demonstrated specific enzyme activity with uridine as the substrate; this activity was inhibited by the competitive inhibitor 2,2'-anhydro-5-ethyluridine. Northern blot analysis with the cDNA as a probe demonstrated high levels of mRNA expression in several tumor cell lines but very low level in normal cell, WI-38. The expression of uridine phosphorylase mRNA in HCT-116 cells was further enhanced by treating the cells with vitamin D3 and the inflammatory cytokines: tumor necrosis factor alpha, interleukin 1 alpha and interferon gamma.


Subject(s)
Gene Expression , Uridine Phosphorylase/biosynthesis , Amino Acid Sequence , Animals , Base Sequence , Calcitriol/pharmacology , Cell Line , Chlorocebus aethiops , Cloning, Molecular , Colorectal Neoplasms , Cytokines/pharmacology , DNA Probes , DNA, Complementary , Gene Expression/drug effects , Humans , Interferon-gamma/pharmacology , Interleukin-1/pharmacology , Kinetics , Mice , Molecular Sequence Data , RNA, Messenger/biosynthesis , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Reference Values , Sequence Homology, Amino Acid , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/pharmacology , Uridine Phosphorylase/chemistry , Uridine Phosphorylase/metabolism
16.
J Gastroenterol ; 30(4): 534-8, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7550868

ABSTRACT

Hepatitis E is endemic in developing countries and may occur as imported hepatitis in industrialized countries. A 46-year-old Japanese man developed immunoserologically diagnosed acute hepatitis E in Japan 4 months after he had made a trip to China. He had bought a Chinese herbal medicine there, taking it occasionally until approximately 6 weeks prior to the onset of acute hepatitis. Nucleotide sequencing of the 3' terminal region of the viral cDNA amplified from the patient's serum by polymerase chain reaction revealed a high degree of homology (99.8% of 752 nucleotides) with the Chinese strain. Thus, the results of sequencing suggest that his hepatitis E was caused by infection with the Chinese strain, via the Chinese herbal medicine.


Subject(s)
Drugs, Chinese Herbal/adverse effects , Hepatitis E/transmission , Acute Disease , Base Sequence , DNA, Complementary/analysis , Drug Contamination , Hepatitis E/virology , Hepatitis E virus/isolation & purification , Humans , Male , Middle Aged , Molecular Sequence Data
17.
Crit Care Med ; 23(6): 1090-8, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7774221

ABSTRACT

OBJECTIVE: To determine whether low-dose dopamine infusion (5 micrograms/kg/min) during cardiopulmonary bypass selectively increases perfusion to the kidney, splanchnic organs, and brain at low (45 mm Hg) as well as high (90 mm Hg) perfusion pressures. DESIGN: Randomized crossover trial. SETTING: Animal research laboratory in a university medical center. SUBJECTS: Ten female Yorkshire pigs (weight 29.9 +/- 1.2 kg). INTERVENTION: Anesthetized pigs were placed on normothermic cardiopulmonary bypass at a 100-mL/kg/min flow rate. After baseline measurements, the animal was subjected, in random sequence, to 15-min periods of low perfusion pressure (45 mm Hg), low perfusion pressure with dopamine (5 micrograms/kg/min), high perfusion pressure (90 mm Hg), and high perfusion pressure with dopamine. Regional perfusion (radioactive microspheres) was measured in tissue samples (2 to 10 g) from the renal cortex (outer two-third and inner one-third segments), stomach, duodenum, jejunum, ileum, colon, pancreas, and cerebral hemispheres. MEASUREMENTS AND MAIN RESULTS: Systemic perfusion pressure was altered by adjusting pump flow rate (r2 = .61; p < .05). In the kidney, cortical perfusion pressure increased from 178 +/- 16 mL/min/100 g at the low perfusion pressure to 399 +/- 23 mL/min/100 g at the high perfusion pressure (p < .05). Perfusion pressure augmentation increased the ratio of outer/inner renal cortical blood flow from 0.9 +/- 0.1 to 1.2 +/- 0.1 (p < .05). At each perfusion pressure, low-dose dopamine had no beneficial effect on renal perfusion or flow distribution. Similar results were found in the splanchnic organs, where regional perfusion was altered by perfusion pressure but not by dopamine. In contrast, neither changing perfusion pressure nor adding low-dose dopamine altered blood flow to the cerebral cortex. CONCLUSIONS: These data indicate that the lower autoregulatory limits of perfusion to the kidneys and splanchnic organs differ from those limits to the brain during normothermic bypass. Selective vasodilation from low-dose dopamine was not found in renal, splanchnic, or cerebral vascular beds. Increasing the perfusion pressure by pump flow, rather than by the addition of low-dose dopamine, enhanced renal and splanchnic but not cerebral blood flows during cardiopulmonary bypass.


Subject(s)
Blood Pressure , Cardiopulmonary Bypass/methods , Cerebrovascular Circulation/physiology , Dopamine/pharmacology , Renal Circulation/physiology , Splanchnic Circulation/physiology , Animals , Blood Pressure/drug effects , Cerebrovascular Circulation/drug effects , Cross-Over Studies , Dopamine/administration & dosage , Drug Evaluation, Preclinical , Female , Homeostasis , Infusions, Intravenous , Random Allocation , Renal Circulation/drug effects , Splanchnic Circulation/drug effects , Swine
18.
J Biol Chem ; 269(3): 2075-81, 1994 Jan 21.
Article in English | MEDLINE | ID: mdl-8294459

ABSTRACT

To determine the expression of various protein-tyrosine phosphatases (PTPs) in human gastric cancers, cDNAs encoding conserved PTP domains were amplified by reverse transcriptase polymerase chain reaction from KATO-III cell mRNA and sequenced. Among 72 polymerase chain reaction clones, one of the cDNA sequences encoded a novel potential PTP (stomach cancer-associated PTP, SAP-1). The full length (3.9 kilobases) of the SAP-1 cDNA was further isolated from the KATO-III cell cDNA library and the WiDr cell cDNA library. The predicted amino acid sequence of the SAP-1 cDNA showed that mature SAP-1 consisted of 1093 amino acids and a transmembrane-type PTP, which possessed a single PTP-conserved domain in the cytoplasmic region. The extracellular region of SAP-1 consisted of eight fibronectin type III-like structure repeats and contained multiple N-glycosylation sites. These data suggest that SAP-1 is structurally similar to HPTP beta and that SAP-1 and HPTP beta represent a subfamily of transmembrane-type PTPs. SAP-1 was mainly expressed in brain and liver and at a lower level in heart and stomach as a 4.2-kilobase mRNA, but it was not detected in pancreas or colon. In contrast, among cancer cell lines tested, SAP-1 was highly expressed in pancreatic and colorectal cancer cells. The bacterially expressed SAP-1 fusion protein had tyrosine-specific phosphatase activity. Immunoblotting with anti-SAP-1 antibody showed that SAP-1 is a 200-kDa protein. In addition, transient transfection of SAP-1 cDNA to COS cells resulted in the predominant expression of a 200-kDa protein recognized by anti-SAP-1 antibody. SAP-1 is mapped to chromosome 19 region q13.4 and might be related to carcinoembryonic antigen mapped to 19q13.2.


Subject(s)
Gastrointestinal Neoplasms/enzymology , Membrane Proteins/biosynthesis , Protein Tyrosine Phosphatases/biosynthesis , RNA, Messenger/biosynthesis , Receptors, Cell Surface , Amino Acid Sequence , Base Sequence , Cell Line , Cell Membrane/enzymology , Cloning, Molecular/methods , Conserved Sequence , DNA Primers , DNA, Complementary/metabolism , Gene Expression , Humans , In Situ Hybridization, Fluorescence , Membrane Proteins/genetics , Molecular Sequence Data , Polymerase Chain Reaction , Protein Tyrosine Phosphatases/genetics , RNA, Messenger/metabolism , Receptor-Like Protein Tyrosine Phosphatases, Class 3 , Sequence Homology, Amino Acid , Stomach Neoplasms/enzymology , Tumor Cells, Cultured
19.
Surgery ; 108(2): 248-52; discussion 252-3, 1990 Aug.
Article in English | MEDLINE | ID: mdl-2382224

ABSTRACT

We have investigated the effect of total denervation of the jejunoileum (JDNv) on stimulated release of peptide YY (PYY) and cholecystokinin-33/39 in five dogs prepared with chronic gastric and duodenal cannulas. JDNv was performed by stripping the adventitia from the superior mesenteric artery and vein, transecting the small bowel mesentery, and division (with reanastomosis) of the small bowel at the ligament of Treitz and ileocecal junctio. Introduodenal corn oil (3 ml/kg/hr) was given before JDNv and 1 and 2 months after JDNv. Intravenous bombesin (400 pmol/kg/hr) was given (on nonconsecutive days) before JDNv and 1 month after JDNv. Plasma PYY and cholecystokinin levels were measured by specific radioimmunoassay. Release of PYY was enhanced after JDNv. The integrated release of PYY (ng.[0 to 60 min]/ml) after intraduodenal corn oil was as follows: before JDNv, 4.1 +/- 1.2; 1 month after JDNv, 16.0 +/- 2.7; and 2 months after JDNv, 10.3 +/- 2.2. Similar results were noted with intravenous bombesin (3.7 +/- 0.9 [before JDNv] vs 12.0 +/- 0.7 [1 month after JDNv]). Corn oil-stimulated release of cholecystokinin was abolished after JDNv (before JDNv 2.2 +/- 1.1; 1 month after JDNv, 0.6 +/- 0.3; and 2 months after JDNv, 0.4 +/- 0.6). Basal plasma levels of PYY and cholecystokinin were not affected by JDNv. We conclude that JDNv enhances PYY and abolished cholecystokinin release, which provides evidence for different mechanisms of neural control.


Subject(s)
Cholecystokinin/metabolism , Denervation , Dietary Fats/pharmacology , Ileum/innervation , Jejunum/innervation , Peptides/metabolism , Animals , Bombesin/pharmacology , Corn Oil/pharmacology , Dogs , Female , Gastrointestinal Hormones/metabolism , Ileum/metabolism , Jejunum/metabolism , Male , Peptide YY , Peptides/blood
20.
J Clin Invest ; 86(1): 323-31, 1990 Jul.
Article in English | MEDLINE | ID: mdl-1694866

ABSTRACT

Bile salts in the intestinal lumen act to inhibit the release of cholecystokinin (CCK). Recent studies have shown that CCK may play a permissive role in the development of acute pancreatitis. In this study, the amount of luminal bile salts in female Swiss Webster mice was either decreased by feeding 4% (wt/wt) cholestyramine or increased by feeding 0.5% sodium taurocholate for 1 wk. Plasma levels of CCK were stimulated by cholestyramine and inhibited by taurocholate. Then, acute pancreatitis was induced either by caerulein injections, or by feeding a choline-deficient, ethionine-supplemented (CDE) diet. Feeding of cholestyramine significantly decreased survival from 25% to 0% in the CDE pancreatitis, and increased the magnitude of elevation of serum amylase levels and the extent of pancreatic necrosis in both models of pancreatitis; CCK-receptor blockade with CR-1409 completely abolished the adverse effects of cholestyramine. In contrast, feeding of taurocholate significantly increased survival to 100% and decreased the elevation of serum amylase and pancreatic necrosis; CCK-8 antagonized these actions of taurocholate. Luminal bile salts appear to provide a physiologic protection against necrotizing pancreatitis, at least in part, both by inhibiting the release of CCK and by promoting resistance of the pancreas to CCK excessive stimulation in vivo.


Subject(s)
Bile Acids and Salts/physiology , Pancreatitis/drug therapy , Acute Disease , Amylases/blood , Animals , Ceruletide/pharmacology , Cholecystokinin/blood , Cholestyramine Resin/administration & dosage , Choline Deficiency/physiopathology , Feedback , Female , Mice , Pancreatitis/pathology , Taurocholic Acid/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL